Antares Pharma Announces New Proprietary Dermatological Drug Delivery System.EXTON, Pa. -- Antares Pharma Inc. (Amex:AIS) announced today the development of the TecTix(TM) drug delivery system for topical and transmucosal delivery of active pharmaceutical agents. The TecTix system is based on transiently reducing the melting point of an active drug by using a combination of known chemical compounds as special permeation enhancers. Reducing the melting point of a drug with our TecTix system, typically results in increased skin permeation, which in the near term should allow Antares to develop novel products specifically targeted for proprietary dermatological and mucosal delivery applications. Our TecTix system has been successfully tested in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment. in vi·tro adj. In an artificial environment outside a living organism. on numerous drug models, including AP-1118, a local anaesthetic an·aes·thet·ic adv. & n. Variant of anesthetic. anaesthetic or US anesthetic Noun a substance that causes anaesthesia Adjective causing anaesthesia where concentration in the dermis dermis: see skin. was increased by +236%, improving the topical to systemic absorption ratio. The benefits of TecTix have also been confirmed in AP-1110, another of our local skin anaesthetics where the melting point was decreased by more than 50 degrees C, causing it to spontaneously melt at room temperature. In addition to its potential compatibility with numerous active drugs and superior melting point depressant depressant, any one of various substances that diminish functional activity, usually by depressing the nervous system. Barbiturates, sedatives, alcohol, and meprobamate are all depressants. Depressants have various modes of action and effects. effect, the TecTix system also is believed to possess several unique efficacy characteristics in delivering drug substances to specific areas of the skin or mucosa. Patent applications have also been filed on behalf of the TecTix system. Dario Carrara, Ph.D., Managing Director for Antares Pharma's Pharmaceutical operations, commented, "The very promising results obtained from pre-clinical testing support our belief that the TecTix system can be successfully applied to numerous therapeutic areas. As a substantially alcohol-free delivery system, TecTix appears to be a perfect match for dermatological products targeting different layers of the skin or mucosa, without utilizing potentially irritating excipients excipients, n.pl all the constituents of a remedy that lack medicinal properties. See also adjuvant, auxiliary substance, and vehicle. ." Mr. Jack Stover stover stalks of maize plants from which mature corn cobs have been harvested as grain, or grain sorghum plants from which heads have also been removed. The stover is usually fed by turning the cattle into the field and is subject to fungal infection, sometimes causing mycotoxicosis. , President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Antares Pharma added, "The TecTix system provides Antares with another significant complement to its ATD ATD Anthropomorphic Test Dummy ATD Attention to Detail ATD Advanced Technology Demonstration AtD Achieving the Dream ATD Atmospheric Technology Division (US National Center for Atmospheric Research) ATD Assistant Technical Director (TM) Advanced Transdermal Delivery system transdermal delivery system: see skin patch. platform and further enhances our intellectual property portfolio and growing product pipeline." About Antares Pharma Antares Pharma is a specialized pharma product development company focused on developing patented drug delivery systems and injectable device engineering capabilities. Antares' current system platforms include its recently announced TecTix(TM) system for topical and transmucosal delivery, ATD(TM) Advanced Transdermal Delivery system, Easy Tec(TM) oral fast-melt system, and subcutaneous injection system platforms including both Vibex(TM) disposable mini-needle injection device and Valeo(TM)/Vision(R) reusable needle-free injection devices. Antares Pharma is committed to leveraging its multiple drug delivery platforms to add value to existing drugs and to create new pharmaceutical products and injectable devices. Overall, Antares' product pipeline will address unmet medical needs by reducing side effect profiles, improving safety, increasing effectiveness, and improving patient compliance and convenience. Antares Pharma has corporate headquarters in Exton, Pennsylvania, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The Company cautions readers that forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ materially and which are identified from time to time in the Company's reports filed with the U.S. Securities and Exchange Commission. Antares Pharma claims the protection of the Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion